Clinical trials / NCT06468124
Recruiting

Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases

The aim of the study is to generate patient-derived organoids (PDOs) from brain resection or biopsied extra-cranial metastases. The preliminary data collected will be used to assess the ability of PDOs to predict patients' treatment response and their radio-sensitivity and chemo-sensitivity can be correlated with their survival outcome.

ClinicalTrials.gov IDNCT06468124
PhaseNot Applicable
Enrollment20
SponsorKing's College London
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Breast Neoplasms

About this study

The aim of the study is to generate patient-derived organoids (PDOs) from brain resection or biopsied extra-cranial metastases. The preliminary data collected will be used to assess the ability of PDOs to predict patients' treatment response and their radio-sensitivity and chemo-sensitivity can be correlated with their survival outcome.

Primary outcomes

Eligibility information

Inclusion Criteria: * Breast cancer patients with brain metastases who are suitable for surgical resection or Breast cancer patients with extra-cranial metastases undergoing surgical resection or biopsy * Age \> 18 years old Exclusion Criteria: * Patients unable to give informed consent e.g., mental disability or vulnerable adults

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.